SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2003
| Delaware | 000-26301 | 52-1984749 | ||
|
|
||||
| (State or Other | (Commission | (I.R.S. Employer | ||
| Jurisdiction of | File Number) | Identification Number) | ||
| Incorporation) |
| 1110 Spring Street | ||
| Silver Spring, MD | 20910 | |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(301) 608-9292
Item 7. Exhibits
(c) Exhibits
| Exhibit No. | Description of Exhibit | |
| 99 | Press release dated May 6, 2003. |
Item 9. Regulation FD Disclosure.
The information contained in this Item 9 is being furnished to the Securities and Exchange Commission (the “Commission”) pursuant to Item 12 of Form 8-K, “Results of Operations and Financial Condition,” as directed by the Commission in Release No. 34-47583.
On May 6, 2003, United Therapeutics Corporation (the “Company”) issued a press release setting forth its earnings for the Company’s quarterly fiscal period ended March 31, 2003. A copy of this press release is attached hereto as Exhibit 99. The Company does not intend for Exhibit 99 to be incorporated by reference into filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | ||||
| Dated: | May 6, 2003 | By: /s/ Paul A. Mahon Name: Paul A. Mahon Title: General Counsel |
EXHIBIT INDEX
| Exhibit No. | Description of Exhibit | |
| 99 | Press release dated May 6, 2003 |